| O1 | Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab | Michael Fehlings; Suchit Jhunjhunwala, BS, PhD; Marcin Kowanetz, Ph.D.; Bill O'Gorman; Priti S. Hegde, PhD; Jessica Li, Master of Science; Hermi Sumatoh; Boon Heng Lee; Alessandra Nardin, DVM; Leesun Kim; Susan Flynn; Marcus Ballinger, PhD; Evan W. Newell, PhD; Mahesh Yadav, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Neoantigens; T cell; Tumor antigens |
| O2 | Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations | George A. Dominguez, PhD; John Roop; Alex Polo; Anthony J. Campisi, B.S.; Dmitry I. Gabrilovich, MD, PhD; Amit Kumar, PhD | Bioinformatics; Biomarkers; Clinical study; Granulocyte; Immune monitoring; Myeloid cells; MDSC; Solid tumors |
| O3 | Anti-tumor immune responses in metastatic breast cancer exceptional responder patients | Alusha A. Mamchak, PhD; Ngan A. Nguyen, PhD; Danhui Zhang, MD PhD; Felix Chu, MS; Mike Harbell, BS; Beatriz Millare, BS; Kevin S. Williamson; Xiaomu Chen; Xiaobin Tang; Shuwei Jiang; Dongkyoon Kim, BS PhD; Nicole Hasser; Sarah Hippely; Maren K. Levin; Amy Manning-Bog, PhD; Jeff DeFalco; William H. Robinson, MD, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Guy Cavet, PhD; William H. Robinson, MD, PhD; Joyce O’Shaughnessy, MD; | Antibody; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Solid tumors; Tumor antigens |
| O4 | Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma | Adi Diab, MD; Scott Tykodi; Brendan D. Curti, MD; Daniel C. Cho, MD; Michael K. Wong, MD PhD FRCPC; Igor Puzanov, MD, MSCI, FACP; Karl D. Lewis, MD; Michele Maio, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Mary A. Tagliaferri, MD; Alison L. Hannah, MD; Wendy Clemens, PhD; Michael Imperiale; Chantale Bernatchez; Cara Haymaker, PhD; Salah Eddine Bentebibel; Jonathan Zalevsky, PhD; Ute Hoch, PhD; Christie Fanton, PhD; Ahsan N. Rizwan, MPharm, PhD; Sandra Aung, PhD; Fiore Cattaruzza; Ernesto Iaccucci; Dariusz Sawka; Mehmet A. Bilen, MD; Paul Lorigan; Giovanni Grignani; James Larkin, MD; Sekwon Jang, MD; Ewa Kalinka-Warzocha, PhD, MD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD | Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O5 | B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB) | Sangeetha M. Reddy, MD, MSci; Beth Helmink, MD PhD; Jianjun Gao, MD PhD; Shaojun Zhang, PhD; Keren Yizhak; Moshe Sade-Feldman; Jorge M. Blando, DVM; Guangchun Han; Vancheswaran Gopalakrishnan, MPH, PhD; Hao Zhao; Wenbin Liu; Hussein A. Tawbi, MD, PhD; Rodabe N. Amaria, MD; Michael Davies, MD, PhD; Patrick Hwu, MD; Jeffrey E. Lee, MD; Jeffrey E. Gershenwald, MD; Scott Woodman; Elizabeth Burton; Lauren E. Haydu, MS, BChe, MIPH; Alexander J. Lazar, MD, PhD; Courtney Hudgens, MS; Alexandria P. Cogdill, MEng; Oscar Krijgsman, PhD; Elisa A. Rozeman, MD; Daniel Peeper, PhD; Christian U. Blank, MD; Ton N. Schumacher, PhD; Emily Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N. Spencer, PhD; Lisa H. Butterfield, PhD; James P. Allison, PhD; Michael T. Tetzlaff, MD PhD; Florent Petitprez, MS; Wolf Herman Fridman, MD, PhD; Catherine Sautes-Fridman, PhD; Nir Hacohen, PhD; Padmanee Sharma, MD, PhD; Linghua Wang, PhD; Jennifer A. Wargo, MD, MMSc | B cell; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment |
| O6 | Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis | Steve Lu, B.S.; Ludmila Danilova, PhD; David L. Rimm, MD, PhD; Clifford C. Hoyt, MS; Matthew Hellmann, MD; Janis M. Taube, MD, MSC | Biomarkers; Checkpoint blockade; Gene expression; Solid tumors; Tumor microenvironment |
| O7 | The personal vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo tumor-related immunity in patients with advanced cancer | Siwen Hu-Lieskovan, MD, PhD; Ramaswamy Govindan, MD; Aung Naing, MD, FACP; Terence Friedlander, MD; Kim A. Margolin, MD; Jessica J. Lin, MD; Nina Bhardwaj, MD, PhD; Matthew Hellmann, MD; Lakshmi Srinivasan, Ph.D; Joel Greshock; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Patrick A. Ott, MD, PhD; | Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| O8 | The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma. | Norbert Hilf, PhD; Sabrina Kuttruff-Coqui, PhD; Katrin Frenzel; Valesca Bukur; Stefan Stevanovic; Cecile Gouttefangeas, PhD; Michael Platten, MD; Ghazaleh Tabatabai; Valérie Dutoit; Sjoerd H. van der Burg, PhD; Per Thor Straten; Francisco Martínez-Ricarte, MD; Berta Ponsati; Hideho Okada, MD, PhD; Ulrik Lassen; Arie Admon; Christian Ottensmeier, MD PhD FRCP; Alexander Ulges; Sebastian Kreiter, MD; Andreas von Deimling; Marco Skardelly; Denis Migliorini; Judith Kroep, MD, PhD; Manja Idorn, PhD; Jordi Rodon; Jordi Piro; Hans S. Poulsen; Bracha Shraibman; Katy McCann; Regina Mendrzyk; Martin Löwer; Monika Stieglbauer; Cedrik Britten, MD; David Capper; Marij JP. Welters; Juan Sahuquillo; Marie Stockhausen; Katharina Kiesel; Evelyna Derhovanessian; Elisa Rusch; Colette Song; Sandra Heesch; Claudia Wagner; Alexandra Kemmer-Brueck; Jörg Ludwig; John Castle; Oliver Schoor, PhD; Jens Fritsche, PhD; Miriam Meyer; Nina Pawlowski, PhD; Sonja Dorner; Franziska Hoffgaard; Bernhard BR. Rössler, Dipl. INg (FH), MBA; Dominik Maurer, PhD; Toni Weinschenk, PhD; Carsten Reinhardt, MD, PhD; Christoph Huber, MD; Hans-Georg Rammensee, PhD; Harpreet Singh, PhD; Ugur Sahin, MD; Pierre-Yves Dietrich; Wolfgang Wick, MD | Clinical trial; Immune adjuvant; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| O9 | Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet | Yu Cao, PhD; Rosa A. Sierra; Jimena Trillo-Tinoco; Carmen Anadon; Wenjie Dai; Eslam Mohamed; Richard Klar, PhD; Sven Michel; Frank Jaschinski, PhD; Shikhar Mehrotra, PhD; Juan R. Cubillos-Ruiz; David H. Munn, MD; Jose R. Conejo-Garcia, MD, PhD; Paulo C. Rodriguez | Adoptive immunotherapy; Gene expression; Immune tolerance; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O10 | Lipid accumulation in the pancreatic tumor microenvironment drives metabolic exhaustion of CD8+ T cells | Teresa Manzo, Kristin G Anderson, Boone Prentice, Aislyn Schalck, Raman Ayush, Breanna M Bates, Andrea Raimondi, Karen C Dwyer, Sara Tucci, Caterina Bartolacci, McClure Marissa, Reyzer Michelle, Jeffery M. Spraggins, N. Heath Patterson, Pier Paolo Scaglioni, Kunal Rai, Carlo Tacchetti, Richard M. Caprioli, Michael Kim, Nicholas E. Navin, Jennifer A. Wargo, Phil Greenberg, Giulio Draetta and Luigi Nezi | Adoptive immunotherapy; Metabolism; T cell; Tumor microenvironment |
| O11 | Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma | Ashley Menk, BS; Yana G. Najjar, MD; John M. Kirkwood, MD; Cindy Sander, BS; Greg M. Delgoffe, PhD | Checkpoint blockade; Metabolism; Tumor microenvironment |
| O12 | Chronic endoplasmic reticulum stress drives mitochondrial exhaustion of CD8 TILs | Kiley A. Lawrence; Jessica Thaxton, PhD, MSCR; Katie E. Hurst; Lee Leddy; Matthew Essman | Checkpoint blockade; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O13 | Lactic acid metabolically supports the high suppressive function of tumor infiltrating regulatory T cells | McLane Watson, BS; Paolo Vignali, BA; Ryan D. Whetstone, MS, PhD; Ronal Peralta; Rahul Deshpande, PhD; Ashley Menk, BS; Nicole E. Scharping, BS; Brett Morrison, MD, PhD; Stacy Wendell, PhD; Greg M. Delgoffe, PhD | Immune suppression; Metabolism; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O14 | Reinvigorating TILs by hyper-oxygenation | Mateusz Rytelewski, PhD; Karine Haryutyunan; Felix Nwajei, PhD; Sergei Vinogradov, PhD; Marina Konopleva, MD, PhD; Tomasz Zal, PhD; Anna Zal | Immune suppression; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O15 | Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors | Kristin G. Anderson, PhD; Shannon K. Oda; Breanna Bates, BS; Madison G. Burnett; Edison Chiu, BS; Magdalia L. Suarez Gutierrez; Nicolas Garcia, BS; Andrew W. Daman; Philip D. Greenberg, MD; | Adoptive immunotherapy; Costimulation; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| O16 | Tscm-like CD8+ T-cells are associated with adoptive TIL therapy response and survival | Matthew Beatty, PhD; Benjamin Schachner; Autumn Joerger; Ellen Scott; Patrick Verdugo; John E. Mullinax, MD; Amod A. Sarnaik, MD; Shari A. Pilon-Thomas, PhD; | Adoptive immunotherapy; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs) |
| O17 | Infusion of TGFβ-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent/metastatic NPC | Christopher DeRenzo, MD; Mamta Kalra; Carlos Ramos; Catherine Robertson; Huimin Zhang; Claudia Gerken; Olga Dakhova; Melinda Mata; Meng-Fen Wu; Hao Liu; Catherine Bollard; Zhuyong Mei; Adrian Gee; Bambi Grilley; Gianpietro Dotti, MD; Helen E. Heslop, MD; Malcolm Brenner; Cliona Rooney; Stephen Gottschalk | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell |
| O18 | Preliminary clinical data from a pilot study of NY-ESO-1c259T-cells in advanced myxoid/round cell liposarcoma | Sandra D'Angelo; Mihaela Druta; David A. Liebner, MD; Scott Schuetze; Brian Van Tine; William Tap; Cedrik Britten, MD; Karen Chagin, MD; Aisha N. Hasan, MBBS MD; Elliot Norry, MD; Trupti Trivedi, MS; Rafael Amado, MD | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| O19 | Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors | Dmitriy Zamarin, MD, PhD; Omid Hamid, MD; Asha Nayak, MD; Solmaz Sahebjam, MD; Mario Sznol, MD; Agron Collaku, PhD; Floyd E. Fox, PhD; Margaret A. Marshall, MD; David Hong, MD; | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| O20 | Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy | Terrence L. Fisher, Jr., PhD; John E. Leonard, MD PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Maria Scrivens; Alan Howell, MS; Leslie Balch, BS; Clint T. Allen, MD; Paul E. Clavijo, PhD; Gregory B. Lesinski, PhD, MPH; Christina Wu, MD; Brian M. Olson, PhD; Siwen Hu-Lieskovan, MD, PhD; Antoni Ribas, MD, PhD; Emily Greengard, MD; Ernest S. Smith, PhD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; Elizabeth E. Evans, PhD; Gregory B. Lesinski, PhD, MPH; | Antibody; Antigen presenting cells; Checkpoint blockade; Immune contexture; Myeloid cells; MDSC; Pediatric tumors; Solid tumors; T cell; Tumor microenvironment |
| O21 | A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma | Diwakar Davar, MD; Peter D. Boasberg, MD, FACP; Zeynep Eroglu, MD; Gerald S. Falchook, MD; Justin F. Gainor, MD; Erika P. Hamilton, MD; J. Randolph Hecht, MD; Jason J. Luke, MD, FACP; Michael Pishvaian; Antoni Ribas, MD, PhD; Judy S. Wang, MD; Kristen McEachern, PhD; Angela Waszak; Sharon Lu; Yong Li; Ying Wang; Patricia LoRusso, DO | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors; T cell; Targeted therapy |
| O22 | Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors | Amod A. Sarnaik, MD; Sajeve Thomas; Diwakar Davar, MD; John M. Kirkwood, MD; Harriet Kluger, MD; Jose Lutzky, MD, FACP; Melissa Wilson; Anna C. Pavlick, MD, MBA; Brendan D. Curti, MD; Eric D. Whitman, MD, FACS; Giao Q. Phan, MD; Marc S. Ernstoff, MD; Jason Chesney, MD; Toshimi Takamura, BS; Debora Barton, MD; Sam Suzuki, MS; Lavakumar Karyampudi; Nancy L. Samberg, PhD; Maria Fardis, PhD, MBA | Adoptive immunotherapy; Clinical study; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O23 | Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile | Emiliano Calvo, MD PhD; Jan Schellens; Ignacio Matos; Elena Garralda; Morten Mau-Soerensen; Aaron Hansen; Maria Martinez-Garcia; Martijn Lolkema; Jehad Charo, PhD; Chiara Lambertini; Christoph Mancao; Katrijn Bogman; Cristiano Ferlini, MD; Martin Stern, MD; Willeke Ros, MSc; | Angiogenesis; Antibody; Antigen presenting cells; Clinical study; Clinical trial; T cell |
| O24 | A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors | Charu Aggarwal, MD MPH; Anthony Joshua, MD; Robert L. Ferris, MD, PhD; Scott J. Antonia, MD, PhD; E E. Rahma, MD; Anthony W. Tolcher, MD, FRCP(C); Roger Cohen; Yanyan Lou, MD; Ralph J. Hauke, MD; Nicholas J. Vogelzang, MD; Dan Zandberg, MD; Arash Rezazadeh Kalebasty, MD; Victoria Atkinson, MD; Alex A. Adjei, MD PhD; Mahesh Seetharam; Ariel Birnbaum, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Vinod Ganju, MBBS, FRACP; Riva Bondarenko, PhD; Linda Peng, MS; Tony Wu, PhD; Scott Currence; Jan Baughman, MPH; Ezio Bonvini; Stacie Goldberg, MD; Jon M. Wigginton, MD; Nehal Lakhani, MD, PhD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| O25 | Phase 1 dose-finding study of the anti–TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Talia Golan; Todd M. Bauer, MD; Antonio Jimeno, MD, PhD; Ruth Perets; Jiaxin Niu; James J. Lee, MD, PhD; Mallika Lala; Jennifer Garrus; Zhen Zeng; Elliot Chartash; Jane Healy; Drew Rasco, MD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| O26 | The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study | Nehal Lakhani, MD, PhD; Todd M. Bauer, MD; Anson K. Abraham, PhD; John Luddy; John Palcza, MS; Elliot Chartash; Jane Healy; Amita Patnaik, MD FRCP© | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| O27 | Phase 2 trial of mocetinostat in combination with durvalumab in NSCLC patients with progression on prior checkpoint inhibitor therapy | Melissa L. Johnson, MD; Keith Eaton, MD; Supporting Author - Balazs Halmos, MD; Supporting Author - Edward B. Garon, MD; Supporting Author - Thomas Hensing, MD; Supporting Author - Nisha A. Mohindra, MD; Supporting Author - James Strauss, MD; Supporting Author - Timothy McCarthy; Supporting Author - Rami Owera; Supporting Author - Isan Chen, MD; Supporting Author - Peter Olson; Supporting Author - Demiana Faltaos, PharmD, PhD; Supporting Author - James Christensen; Supporting Author - Diane Potvin; Supporting Author - Tavette Neskorik; Supporting Author - Adam Pavlicek; Presenting Author - Manish R. Patel, DO; Primary Author - Manish R. Patel, DO; | Checkpoint blockade; Clinical trial; Tumor microenvironment |
| O28 | Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma | Frederic Triebel, MD, PhD; Christian Mueller; Chrystelle Brignone; Victoria Atkinson, MD; Melissa Eastgate, MD; Amitesh Roy, MD; Adnan Khattak, MD; Andrew Haydon, MBBS PhD | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
| O29 | Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality | Viola Marschall, PhD; Meinolf Thiemann; Jaromir Sykora; David M. Richards; Christian Merz; Julian P. Sefrin; Karl Heinonen; Matthias Schroeder; Mauricio Redondo Müller; Oliver Hill; Christian Gieffers | Antibody; Costimulation; Regulatory T cell (Treg cell); T cell |
| O30 | First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers | Timothy A. Yap, MD; Capucine Baldini, MD; Christophe Massard, MD, PhD; Ivelina Gueorguieva, PhD; Yumin Zhao, PhD; Shelly L. Schmidt; Michael Man, PhD; Shawn T. Estrem, PhD; Karim A. Benhadji, MD; Maria Vieito, MD | Clinical trial; Cytokine; Inflammation; Solid tumors; Targeted therapy; Tumor microenvironment |
| O31 | Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma | Joanna Pucilowska, PhD; Venkatesh Rajamanickam; Nicole Moxon, RN; Katherine Sanchez, MD; Monil Shah, PharmD; James Imatani, MD; Shaghayegh Aliabadi-Wahle, MD; Maritza Martel, MD; Alison K. Conlin, MD; James E. Egan, PhD; David B. Page, MD | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Gene expression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O32 | Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway | Ting Zhou; William Damsky, MD, PhD; Karen P. Hartmann, MS; Suzanne Fischer, BS; Marcus W. Bosenberg, MD, PhD; Aaron M. Ring | Checkpoint blockade; Costimulation; Cytokine; Gene expression; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O33 | Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity | Hiroshi Yano, BS; Deepali V. Sawant, PhD; Maria Chikina, PhD; Qianxia Zhang, PhD; Zhe Sun; Tao Sun; Wei Chen; Creg Workman, PhD; Dario A. Vignali, PhD; | Bioinformatics; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O34 | Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety | Ling Zhang; John Davies; Carylinda Serna; Zhiya Yu; Nicholas P. Restifo, MD; Steven A. Rosenberg, MD, PhD; Christian S. Hinrichs, MD | Adoptive immunotherapy; Cytokine; T cell |
| O35 | Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity | Esra Akbay, PhD; Juan Miret; Paul Kirschmeier; Shohei Koyama; Yvonne Li; Glenn Dranoff, MD; Peter Hammerman; Chad Pecot; Kwok-Kin Wong, MD, PhD; Esra Akbay, PhD; | Granulocyte; Immune contexture; Immune suppression; Myeloid cells; Metabolism; Solid tumors; Tumor microenvironment |
| O36 | Neuropilin-1 stabilizes human Tregs in cancer patients leading to more potent suppressive function | Christopher A. Chuckran, BS; Anthony R. Cillo, PhD; Jessica Moskovitz, MD; Ashwin Somasundaram, MD; John M. Kirkwood, MD; Francesmary Modugno, PhD; Robert P. Edwards, MD; Robert Schoen, MD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; | Checkpoint blockade; Coinhibition; Costimulation; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O37 | A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer | Li Peng, PhD; Lizhi Cao; Adam Petrone; Lihui Xu, BS; Wayne Galtlin, MS; Michele Mayo; Michal Stanczak; Carolyn Bertozzi; Karl Normington, PhD, MBA; Jeff Brown; Heinz Laubli; Jim W. Broderick, MD; Li Peng, PhD | Antibody; Immune suppression; Targeted therapy; Tumor microenvironment |
| O38 | Remodeling the tumor microenvironment – Targeting Scavenger receptors | Dhifaf Sarhan, PhD; Caroline Driescher, MS.; Silke Sohn, MS.; Salvatore Nania; Rainer Heuchel; Matthias Löhr; Mikael Karlsson | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| O39 | PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy | Gabriel Abril-Rodriguez, MS; Antoni Ribas, MD, PhD; Davis Y. Torrejon, MD; Jesse Zaretsky; Theodore S. Nowicki, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Beata Berent-maoz; Begonya Comin-Anduix, PhD; Catherine S. Grasso; Antoni Ribas, MD, PhD; | Checkpoint blockade; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| O40 | Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion | Erica Stone, PhD; Erin M. O'Brien, MS; Emilio Sanseviero; Jenna Karras, PhD; Tamer Shabaneh; Bulent A. Aksoy, Ph.D.; Wei Xu; Xiaowei Xu; Giorgos Karakousis; Ravi K. Amaravadi, MD; Mark P. Rubinstein, PhD; Mary Jo Turk; Jeffrey Hammerbacher, BA; Lynn M. Schuchter, MD; Tara C. Mitchell; Qin Liu | Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O41 | Tumor-derived GDF-15 which impairs LFA-1 dependent T cell recruitment represents a roadblock and a new target for cancer immunotherapy | Jörg Wischhusen, PhD; Markus MH. Haake, PhD | Antibody; Biomarkers; Checkpoint blockade; Coinhibition; Cytokine; Immune tolerance; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O42 | LSD1 inhibition promotes CD141Hi dendritic cell differentiation in myelodysplastic syndromes | Pragya Srivastava, PhD; Kyle Wiatrowski, BS; Prashant Singh, PhD; Eduardo Cortes Gomez, MS; Jianmin Wang, PhD; Miranda Lynch, PhD; Sheila Sait, PhD; Laurie Ann Ford, BS; Brandon Martens, BS; Linda Lutgen-Dunckley, BS; Elizabeth Griffiths, MD; Michael J. Nemeth, PhD; Stephanie Tzetzo, MA; Scott I. Abrams, PhD; | Dendritic cell; Leukemia/Lymphoma |
| O43 | Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma | Shruthi Naik, PhD; Kelly Makielski, DVM, MS; Michael Henson, DVM, PhD; Kathleen Stuebner; Alexander-Flaviu Tabaran, DVM, MSc, PhD; Ingrid Cornax, PhD; Gerard O'Sullivan, MVB, PhD; Andrea Eckert; Lauren Mills, PhD; Milcah Scott, BS; Aaron L. Sarver, PhD; Michael A. Farrar; Stephen J. Russell, MD, PhD; Jaime F. Modiano, VMD, PhD | Biomarkers; Immune monitoring; Pediatric tumors |
| O44 | FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in vitro and induces potent, FcγR-independent anti-tumour activity | Miguel Gaspar, PhD; Cyril Privezentzev, PhD; Katy Everett, PhD; Sandra Uhlenbroich; John Pravin; Leonor LR. Rodrigues, MSc; Delphine Buffet; Marine Houee; Francisca Wollerton; Melanie Medcalf; Edouard Souteyrand; Alexander Koers, PhD; Emma McConnell, Master in Phyhsiology and Pharmacology for Researc; Martyn C. Rhoades, Mateusz Wydro, PhD; Maud Berthelot, MSc; Sarah Batey; Michael Davies; Jacqueline F. Doody, PhD; Michelle Morrow, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD | Antibody; Costimulation; Immune adjuvant; Regulatory T cell (Treg cell); T cell; T cell lineages |
| O45 | Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444 | Lawrence Fong, MD; John D. Powderly, II, MD, CPI; Jason J. Luke, MD, FACP; Drew Hotson, PhD; Mario Sznol, MD; Saby George, MD, FACP; Toni K. Choueiri; Brian I. Rini, MD; Matthew Hellmann, MD; Shivaani Kummar, MD; Leonel Hernandez-Aya, MD PhD; Daruka Mahadevan, MD, PhD; Brett Hughes, MD; Ben Markman; Matthew Riese, MD, PhD; Joshua Brody, MD; Daniel Renouf, MD; Rebecca Heist, MD; Rachel Goodwin, MD; Amy Weise, DO; Leisha A. Emens, MD, PhD; Stephen Willingham, PhD; Long Kwei, PhD; Ginna G. Laport, MD; Richard A. Miller, MD | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| O46 | Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis | Peter Savas; Balaji Virassamy; Chengzhong Ye; Agus Salim; Chris Mintoff; Franco Caramia; Roberto Salgado; Zhi Ling Teo; Sathana Dushyanthen; Ann Byrne; Stephen J. Luen; Paul Beavis, PhD; Stephen B. Fox; Phillip K. Darcy; Terence P. Speed; Laura K. Mackay; Paul J. Neeson, PhD; Paul J. Neeson, PhD; Sherene Loi, MD, PhD | T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| O47 | Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1 blockade | Jiajia Zhang, MD, MPH; Zhicheng Ji; Margueritta El Asmar, MD; Justina Caushi; Valsamo Anagnostou, MD PhD; Hok Yee N. Chan, MS; Prerna Suri, MS; Haidan N. Guo, BS, and BA; Kristen Marrone, MD; Jarushka Naidoo, MD; Taha Merghoub, PhD; Jamie Chaft, MD; Matthew Hellmann, MD; Janis M. Taube, MD, MSC; Julie R. Brahmer, MD; Victor E. Velculescu, MD, PhD; Ni Zhao; Patrick Forde, MD; Drew M. Pardoll, MD, PhD; Hongkai Ji; Kellie N. Smith, PhD | Bioinformatics; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
